Delineation of the roles of paracrine and autocrine interleukin-6 (IL-6) in myeloma cell lines in survival versus cell cycle. A possible model for the cooperation of myeloma cell growth factors

European Cytokine Network

Volumn 16, Issue 1, 2005, Pages 57-64

  Jourdan, Michel ^a   Mahtouk, Karène ^a   Veyrune, Jean Luc ^b   Couderc, Guilhem ^b   Fiol, Geneviève ^b   Redal, Nicole ^b   Duperray, Christophe ^a   De Vos, John ^a,b   Klein, Bernard ^a,b  

^a INSERM   (France)

^b MONTPELLIER UNIVERSITY HOSPITAL   (France)

Author keywords

Apoptosis; Cell cycle; IL 6; Mcl 1; Myeloma

Indexed keywords

GLYCOPROTEIN GP 130; INTERLEUKIN 6; LIPOCORTIN 5; MESSENGER RNA; PROTEIN MCL 1;

APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; BONE MARROW CELL; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; MONOCYTE; MYELOMA CELL; PARACRINE SIGNALING; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL ANALYSIS;

ANTIBODIES, MONOCLONAL; APOPTOSIS; AUTOCRINE COMMUNICATION; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; HUMANS; INTERLEUKIN-6; MULTIPLE MYELOMA; NEOPLASM PROTEINS; PARACRINE COMMUNICATION; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 16444366375     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Jourdan M, De Vos J, Mechti N, Klein B. Regulation of Bcl-2-family proteins in myeloma cells by three myeloma survival factors: interleukin-6, interferon-alpha and insulin-like growth factor 1. Cell Death Differ 2000; 7: 1244.
2. Gomez-Bougie P, Bataille R, Amiot M. The imbalance between Bim and Mcl-1 expression controls the survival of human myeloma cells. Eur J Immunol 2004; 34: 3156.
3. Klein B, Zhang XG, Lu ZY, Bataille R. Interleukin-6 in human multiple myeloma. Blood 1995; 85: 863.
4. Kawano M, Hirano T, Matsuda T. et al. Autocrine generation and essential requirement of BSF-2/IL-6 for human multiple myeloma. Nature 1988; 332: 83.
5. Klein B, Zhang XG, Jourdan M, et al. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 1989; 73: 517.
6. Uchiyama H, Barut BA, Mohrbacher AF, Chauhan D, Anderson KC. Adhesion of Human Myeloma-Derived Cell Lines to Bone Marrow Stromal Cells Stimulates Interleukin-6 Secretion. Blood 1993; 82: 3712.
7. Caligaris-Cappio F, Bergui L, Gregoretti MG, et al. Role of bone marrow stromal cells in the growth of human multiple myeloma. Stood 1991; 77: 2688.
8. Hata H, Xiao H, Petrucci MT, Woodliff J, Chang R, Epstein J. Interleukin-6 gene expression in multiple myeloma: a characteristic of immature tumor cells. Blood 1993; 81: 3357.
9. Portier M, Rajzbaum G, Zhang XG, et al. In vivo interleukin-6 gene expression in the tumoral environment in multiple myeloma. Eur J Immunol 1991; 21: 1759.
10. Frassanito MA, Cusmai A, Iodice G, Dammacco F. Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis. Blood 2001; 97: 483.
11. Zhang XG, Gaillard JP, Robillard N, et al. Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood 1994; 83: 3654.
12. Shimizu S, Yoshioka R, Hirose Y, Susumu S, Tachibana J, Konda S. Establishment of two interleukin-6 (B cell stimulatory factor 2/interferonbeta2) dependent human bone marrow-derived myeloma cell lines. J Exp Med 1989; 169: 339.
13. Westendorf JJ, Ahmann GJ, Greipp PR, Witzig TE, Lust JA, Jelinek DF. Establishment and characterization of three myeloma cell lines that demonstrate variable cytokine responses and abilities to produce autocrine interleukin-6. Leukemia 1996; 10: 866.
14. Jourdan M, Zhang XG, Portier M, Boiron JM, Bataille R, Klein B. IFN-alpha induced autocrine production of IL-6 in myeloma cell lines. J Immunol 1991; 147: 4402.
15. Ferlin-Bezombes M, Jourdan M, Liautard J, Brochier J, Rossi JF, Klein B. IFN-alpha is a survival factor for human myeloma cells and reduces dexamethasone-induced apoptosis. J Immunol 1998; 161: 2692.
16. Jourdan M, Veyrune JL, De Vos J, Redal N, Couderc G, Klein B. A major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells. Oncogene 2003; 22: 2950.
17. Liautard J, Sun RX, Cotte N, Gaillard JP, Mani JC, Klein B, et al. Specific inhibition of IL-6 signalling with monoclonal antibodies against the gp130 receptor. Cytokine 1997; 9: 233.
18. Collins MKL, Marvel J, Malde P, Lopez-Rivas A. Interleukin-3 protects murine bone marrow cells from apoptosis induced by DNA damaging agents. J Exp Med 1992; 176: 1043.
19. Helle M, Boeise L, Aarden LA. Functional discrimination between interleukin-6 and interleukin-1. Eur J Immunol 1988; 18: 1535.
20. Brenning G. The in vitro effect of leucocyte alpha-interferon on human myeloma cells in a semisolid agar culture system. Scand J Haematol 1985; 35: 178.
21. Jelinek DF, Aagaard-Tillery KM, Arendt BK, Arora T, Tschumper RC, Westendorf JJ. Differential human multiple myeloma cell line responsiveness to interferon-alpha. Analysis of transcription factor activation and interleukin 6 receptor expression. J Clin Invest 1997; 99: 447.
22. Jernberg-Wiklund H, Pettersson M, Carlsson M, Nilsson K. Increase in interleukin 6 (IL-6) and IL-6 receptor expression in a human multiple myeloma cell line, U-266, during long-term in vitro culture and the development of a possible autocrine IL-6 loop. Leukemia 1992; 6: 310.
23. Keller ET, Ershler WB. Effect of IL-6 receptor antisense oligodeoxynucleotide on in vitro proliferation of myeloma cells. J Immunol 1995; 154: 4091.
24. Gu ZJ, Vos JD, Rebouissou C, et al. Agonist anti-gp130 transducer monoclonal antibodies are human myeloma cell survival and growth factors. Leukemia 2000; 14: 188.
25. Mahtouk K, Jourdan M, De Vos J, et al. An inhibitor of the EGF receptor family blocks myeloma cell growth factor activity of HB-EGF and potentiates dexamethasone or anti-IL-6 antibody-induced apoptosis. Blood 2004; 103: 1829.
26. Derksen PW, De Gorter DJ, Meijer HP, et al. The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma. Leukemia 2003; 17: 764.
27. Chesi M, Brents LA, Ely SA, et al. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood 2001; 97: 729.